Genmab — Februar 2020
-
Tusinde tak Cirrus og alle jer andre. Her en en ny videoanalyse med Genmab: https://www.proinvestor.com/debat/81906
-
Egentlig var Jan ret konkret om deres forestilling om en partner (transciptet): "We want a partner, Graig, which already has one or two products on the market in that area. They are potentially ready. They have a very good knowledge already of developing drugs in those areas and has new molecules, which are not yet on the market, but it's prepared toward the market, which can be combined early on already with epcoritamab"
-
GENMAB A/S <GMAB.O>: RBC RAISES PRICE TARGET TO $27 FROM $24 - RTRS | News Wires | Thomson Reuters Eikon
-
GENMAB A/S <GMAB.CO>: GUGGENHEIM CUTS TARGET PRICE TO DKK 1,751 FROM DKK 1,760 - RTRS | News Wires | Thomson Reuters Eikon
-
Også en lille skærv herfra Helge.
-
Sukker, det er Suntrust, der kommer med denne vurdering: Ifølge finanshuset bør Genmab overveje den eksisterende partner Johnson & Johnson, Abbvie eller Bristol-Myers Squibb (BMS) til opgaven med at maksimere lægemiddelprojektet GEN 3013 inden for lymfekræft
-
Tak endnu engang for donationer. I næste uge begynder vi at arbejde på to spritnye servere. 2 x attack og timelange nedbrud som vi har oplevet de seneste 14 dage kan mit nervesystem ikke holde til.:-)
-
Skriv gerne på her: https://www.proinvestor.com/?p=debat_1&postid=81880&thread=50&start=
-
Berenberg dækker ikke Genmab længere
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Stor tak til de velinformerede, delende - og nogen gange underholdende - skribenter. Donation overført. Fra e